{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:01:36Z","timestamp":1773421296298,"version":"3.50.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2642552","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:42:56Z","timestamp":1773416576000},"page":"835-847","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-9426","authenticated-orcid":false,"given":"Caitlin","family":"Montcrieff","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-568X","authenticated-orcid":false,"given":"Jorge","family":"Caicedo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Cerretani","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2967-7636","authenticated-orcid":false,"given":"Angela (Qi)","family":"Fan","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-4576","authenticated-orcid":false,"given":"Michael","family":"Bullano","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-8034","authenticated-orcid":false,"given":"Ekaterina","family":"Ponomareva","sequence":"additional","affiliation":[{"name":"Axtria","place":["Berkeley Heights, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.05.026"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S359510"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01676-w"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14454"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.92369"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044997"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep15010014"},{"key":"e_1_3_2_9_1","unstructured":"CDC. Treatment of Hemophilia|CDC. Centers for Disease Control and Prevention. Available from: https:\/\/www.cdc.gov\/hemophilia\/treatment\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/treatment.html"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S252580"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1574743"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005673"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19406"},{"key":"e_1_3_2_15_1","unstructured":"Medical and Scientific Advisory Council (MASAC). Recommendation on the use and management of emicizumab\u2011kxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors (MASAC Document No. 268). National Bleeding Disorders Foundation; 2022 Apr 27 [cited 2026 Mar 9]. Available from: https:\/\/www.bleeding.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100074"},{"key":"e_1_3_2_17_1","unstructured":"Chugai\u2019s Hemlibra receives approval for severe hemophilia A without factor VIII inhibitors from the European Commission. Chugai Pharmaceuticals; 2019. Available from: https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20181221153002_580.html"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2102779"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102717"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0278"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14005"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14212"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102693"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.6.626"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0109"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.11.017"},{"key":"e_1_3_2_27_1","unstructured":"CMS Medicaid Data [Internet]. data.medicaid.gov; 2023 [accessed 2025 Apr 4]. Available from: Pricing Comparison for Blood Disorder Treatments (Pricing as of 12\/1\/2024)"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab158"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2019.04.236"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.969"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00932.x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s12187381"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03270.x"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231218624"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2642552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:43:01Z","timestamp":1773416581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2642552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2642552"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2642552","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}